

1     **Genetics and genetic testing for age-related macular degeneration**

2     Alasdair Warwick MBBS BSc<sup>1</sup>

3     Andrew Lotery MD FRCOphth<sup>2, 3 \*</sup>

4     <sup>1</sup>Moorfields Eye Hospital, 162 City Road, London EC1V 2PD

5     <sup>2</sup>Faculty of Medicine, Clinical and Experimental Sciences, University of Southampton, Southampton  
6     SO16 6YD, UK

7     \*Author to whom correspondence should be addressed; Email: [a.j.lotery@soton.ac.uk](mailto:a.j.lotery@soton.ac.uk); Tel: +44-238-  
8     079-5049; Fax: +44-238-079-4542

9     Conflict of interest: none to declare

10    Funding: none

11    Running title: Genetics and genetic testing for age-related macular degeneration

12

13

14    Word count: 3735

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31    **Abstract**

32    Considerable advances have been made in our understanding of age-related macular degeneration  
33    (AMD) genetics over the past decade. The genetic associations discovered to date are estimated to  
34    account for approximately half of AMD heritability and functional studies of these variants have  
35    revealed new insights into disease pathogenesis, leading to the development of potential novel  
36    therapies. There is furthermore growing interest in genetic testing for predicting an individual's risk  
37    of AMD and offering personalised preventive or therapeutic treatments. We review the progress  
38    made so far in AMD genetics and discuss the possible applications for genetic testing.

39

40

41

42

43

44

45

46

47

48

49

50

51

52

## 53     **Introduction**

54     Age-related macular degeneration (AMD) is the commonest cause of blindness in the developed  
55     world, affecting 5% of those aged >75 years old and an estimated 150 million people worldwide.<sup>1, 2</sup>

56     Disease onset is in later life, typically after the age of 60 years, and is characterised clinically by  
57     retinal pigmentary change and the appearance of drusen at the macula. Central vision may  
58     subsequently decline either gradually with progressive geographic retinal atrophy (GA), or acutely  
59     due to retinal haemorrhage and fluid exudation from choroidal neovascularisation (CNV) if  
60     neovascular AMD (nvAMD) develops. While the latter may now be effectively treated with  
61     intravitreal anti-vascular endothelial growth factor (VEGF) injections, there is currently no therapy  
62     for GA available in clinical practice.<sup>3</sup>

63     Over the past decade considerable progress has been made in elucidating the genetic architecture of  
64     AMD. The discovery of multiple genetic associations and studies of their downstream functional  
65     consequences has helped reveal new underlying pathophysiological mechanisms in AMD, affording  
66     the potential to identify molecular targets for novel therapies. The complement pathway in  
67     particular, an important component of the innate immune system, has been consistently  
68     implicated.<sup>4</sup> Furthermore, there is growing interest in genetic testing to predict either an individual's  
69     risk of developing AMD or how well they will respond to treatment. Ultimately this could mean that  
70     in the future patients are offered personalised preventive or therapeutic treatments, tailored to  
71     their individual genetic makeup. In this review, we summarise the current literature and possible  
72     future directions for AMD genetics and genetic testing.

## 73     **Genetics of AMD**

74     AMD is a complex disease with multiple environmental and genetic risk factors. The most  
75     consistently associated environmental risk factors are age and smoking, although gender, race,  
76     cardiovascular disease and diet have also been implicated.<sup>5</sup> Evidence for a genetic component was  
77     supported by family aggregation studies and twin studies. In family aggregation studies, the

78 prevalence of AMD was higher in first degree relatives of AMD patients (23.7%) compared with  
79 relatives of controls (11.6%), with an odds ratio (OR) of 2.4.<sup>6</sup> By comparing disease concordance  
80 rates between monozygotic and dizygotic twins, the heritability of early and advanced AMD has  
81 been estimated at 46% and 71% respectively, implying 46-71% of AMD variation may be explained  
82 by genetic factors.<sup>7</sup>

83 In early efforts to explore AMD genetics, association studies were performed for candidate genes  
84 known to cause Mendelian macular diseases such as Best's disease, Stargardt's disease and Sorsby's  
85 fundus dystrophy. However, no consistent significant associations were made.<sup>8-11</sup> Other groups  
86 undertook genetic linkage studies of patient families to identify genomic regions containing  
87 susceptibility loci for AMD. A meta-analysis of these results showed the most replicated findings  
88 were on chromosomes 1q25-31 and 10q26.<sup>12</sup> Their importance was then validated by subsequent  
89 findings of specific AMD-associated common genetic variants at these two loci – the complement  
90 factor H (*CFH*) gene on chromosome 1 and the age-related maculopathy susceptibility 2/HtrA serine  
91 peptidase (*ARMS2/HTRA1*) genes on chromosome 10.

## 92 ***Common variants***

93 Technological advancements enabling the analysis of whole genomes, rather than individual genes,  
94 have greatly accelerated the discovery of new genetic associations with common complex genetic  
95 diseases such as AMD. Genome-wide association studies (GWAS) examine a genome-wide set of  
96 genetic variants, typically single nucleotide polymorphisms (SNPs), for associations with the disease  
97 of interest. Whereas genetic linkage studies are effective for investigating high penetrance single  
98 gene defects underlying rare monogenic disorders, GWASs are better able to detect low penetrance  
99 common genetic variants (with a minor allele frequency (MAF) >5%) associated with complex  
100 genetic diseases.

101 In 2005 landmark studies associated a common polymorphism (Tyr402His, or Y402H) in the *CFH*  
102 gene on chromosome 1 with AMD.<sup>13-16</sup> One of these was the first GWAS performed for AMD,

showing that the Y402H risk allele had a large effect size (4.6 and 7.4 increased likelihood of AMD in heterozygous and homozygous individuals respectively).<sup>16</sup> Of note this was the first successful GWAS of a 'complex disease' i.e. one with both genetic and environmental factors contributing significantly to disease. As such it represented a major success for genetic approaches to studying common diseases. Subsequent GWASs and candidate gene studies have since associated several other common variants in complement-related genes with AMD, including *C2/CFB*,<sup>17</sup> *C3*,<sup>18</sup> *C7*,<sup>19</sup> *CFI*<sup>20</sup> and *SERPINE1*.<sup>21</sup>

The complement cascade encompasses a family of more than 30 circulating proteins and their regulators which form an important part of the innate immune system. Activation of the complement cascade ultimately results in formation of the membrane attack complex (MAC), which induces cell lysis. While the liver is the major source of systemic complement, retinal cells synthesise their own complement<sup>22</sup> and complement proteins have been detected in drusen from human eyes.<sup>23-25</sup> Raised systemic levels of complement have also been reported in AMD patients versus controls<sup>26</sup> and interestingly patients with dense deposit disease, a renal condition associated with systemic complement dysregulation and glomerular C3 deposition, often develop drusen.<sup>27, 28</sup> However locally produced, rather than systemic, complement appears likely to be more important in AMD.<sup>26, 29</sup>

Chronic intraocular complement-mediated inflammation in genetically susceptible individuals exposed to environmental triggers, such as cigarette smoke and oxidative stress, may contribute to the progressive retinal changes observed in AMD. While the functional relevance of most common AMD-associated genetic variants remains unknown, a common missense polymorphism in *C3* has been shown to result in reduced binding to CFH, a plasma regulator of complement, and increased activity of the alternative complement pathway.<sup>30</sup> Furthermore, a number of studies have looked at the functional effects of the non-synonymous *CFH* Y402H polymorphism. The minor allele, encoding a histidine amino acid at residue 402 of the CFH protein, alters its affinity for CRP,<sup>31</sup>

glycosaminoglycans in Bruch's membrane,<sup>32, 33</sup> malondialdehyde<sup>34</sup> and zinc.<sup>35</sup> These changes are thought to decrease its ability to regulate complement. Reduced complement regulation may lead to increased MAC deposition and choroidal endothelial cell death, impairing the ability of the choriocapillaris to remove debris and allowing the accumulation of waste products in drusen.<sup>4</sup> In support of this theory, eyes homozygous for the *CFH* Y402H risk variant have thinner choroids<sup>36</sup> and increased MAC deposition<sup>37</sup> at the choriocapillaris compared with eyes with low-risk *CFH* genotypes.

Genes not involved in the complement pathway have also been associated with AMD. The *ARMS2/HTRA1* locus on chromosome 10q26 has been strongly associated, risk alleles conferring an OR of 5.0 and a population attributable risk up to 57%.<sup>38, 39</sup> As both genes at this region are in strong linkage disequilibrium with each other and both harbour functional variants which could plausibly be relevant to AMD, dissecting out which is responsible for the observed association with AMD has proved challenging.<sup>40</sup> Recently however, analysis of the largest data set for AMD genetics to date suggested that genetic variants at *ARMS2*, but not *HTRA1*, are responsible for AMD susceptibility at the 10q26 locus.<sup>41</sup> Further functional analysis of *ARMS2* is required to understand its role in AMD pathogenesis. Other non-complement associations with AMD include genes implicated in angiogenesis (*TGFBR1*, *VEGFA*), the extracellular collagen matrix (*COL10A1*, *COL8A1*), the high density lipoprotein cholesterol pathway (*APOE*, *CETP*, *LIPC*) and immune regulation (*PILRB*).<sup>42-44</sup>

#### **Rare variants**

In 2013 the AMD Gene Consortium published the largest GWAS for AMD conducted up until that time, evaluating >2.4 million SNPs in >17,100 cases and >60,000 controls. However they estimated that only 15-65% of AMD heritability was explained by the 19 loci discovered.<sup>42</sup> Several theories seeking to explain missing heritability exist, including gene-environment interactions, gene-gene interactions, epigenetics, copy number variation and rare variants.<sup>45</sup> In particular, the focus of genetic research for complex diseases in general has shifted toward identifying low-frequency (MAF 1-5%) and rare variants (MAF≤1%) with relatively large effect sizes.<sup>46</sup> Furthermore, a recent

simulation study demonstrated that the clustering of AMD in densely affected families was insufficiently explained by the genotypic load of common genetic risk variants and that rare variants may be more important.<sup>47</sup>

Various approaches have been successful in discovering new rare genetic variants associated with AMD. Next generation sequencing technology can be used to comprehensively analyse variation within candidate genes between cases and controls. The first rare variant to be associated with AMD, *CFH* R1210C, was identified in this way.<sup>48</sup> It demonstrated high penetrance (present in 40 cases versus 1 control,  $p = 7.0 \times 10^{-6}$ , OR 18.8) and was associated with earlier onset of disease. Similar studies have also identified rare variants in *CFI*, *C3* and *C9*.<sup>49-51</sup> Whole exome or whole genome sequencing is expensive to carry out in large numbers but has been performed in an Icelandic case-control cohort<sup>52</sup> as well as in large AMD families, thought to be enriched for rare variants.<sup>53-59</sup> In 2016 the International AMD Genomics Consortium (IAMGCG) identified 52 independently associated common and rare variants distributed across 34 loci.<sup>44</sup> The group performed a GWAS using an exome chip, customised to analyse >12 million variants (including >163,700 directly genotyped, mostly rare, protein-altering variants) in >16,100 patients and >17,800 controls. This is the largest study of AMD genetics performed to date, more than doubling the number of known associated variants and identifying the first variant specific to one advanced AMD phenotype (*MMP9* and nvAMD). Rare variants were discovered in *CFH* and *CFI*, as well as the non-complement genes *TIMP3* and *SLC16A8*.<sup>44</sup>

Compared with common variants, highly penetrant rare variants often have clearer functional effects.<sup>60</sup> For example, in a large advanced AMD cohort rare *CFH* variants tended to be located in functional domains and resulted in low CFH serum levels.<sup>61</sup> Rare variants in *CFI*, another regulator of the complement system, have also been associated with decreased serum CFI levels<sup>54</sup> and carriers of rare variants in both *CFH* and *CFI* have impaired ability to regulate complement activation.<sup>54, 59</sup> Furthermore, the rare *C3* Lys155Gln variant has been shown to impair C3b regulation by CFI with

bound *CFH*.<sup>49</sup> Overall these findings support the hypothesis that increased complement activity may contribute to AMD pathogenesis.

Carriers of rare variants appear to have differing phenotypes compared with non-carriers. A number of studies have shown rare variants to be associated with earlier onset of advanced AMD.<sup>48, 58, 59, 62, 63</sup> Carriers of rare *CFH* variants have increased drusen load, are more likely to have extramacular drusen, drusen nasal to the optic disc and crystalline or calcified drusen.<sup>62-64</sup> In addition, rare variants in *CFH*, *CFI*, *C9* and *C3* have been more frequently observed in patients with GA than those with nvAMD.<sup>58, 63</sup> Interestingly a rare missense mutation in *TIMP3* (C1113G), identified by the IAMDGC, is associated with earlier age of disease onset (average age 65 years) and bilateral CNV.<sup>65</sup> Other mutations in *TIMP3* cause Sorsby's fundus dystrophy, an autosomal dominant fundus dystrophy characterised by a similar clinical phenotype to AMD, although typically age of onset is in the fourth decade of life. Further genotype-phenotype correlations are needed to determine whether the phenotype associated with this mutation more closely resembles AMD or Sorsby's fundus dystrophy. The IAMDGC estimate that the 52 currently known variants account for approximately half the genomic heritability of AMD.<sup>44</sup> Despite this significant progress there is still therefore a large portion of missing heritability. The IAMDGC highlight the need for very large sample sizes and extensive genome coverage in population studies looking for novel rare variants in complex diseases. Future studies looking at other potential sources of missing heritability and functional studies of known associated variants are also needed.

### **Genetic testing for AMD**

As the list of known AMD-associated genetic variants continues to grow, so too does interest in developing predictive risk models incorporating these alleles. The ability to accurately predict a person's risk of developing AMD would be an important step towards personalised medicine, allowing appropriate preventive measures to be taken in high-risk individuals. Pharmacogenetic testing could furthermore help identify which AMD patients are most likely to benefit from certain



treatments. For example, it is conceivable that novel therapies modulating the complement system may be most effective in patients harbouring complement-related risk alleles.

### ***Genetic risk models for AMD***

In contrast to rare monogenic disorders, complex genetic diseases such as AMD are associated with multiple environmental and genetic risk factors. Possession of an allele known to be associated with disease increases an individual's risk of developing the condition and possessing multiple risk alleles or exposure to certain environmental triggers may further increase this risk. Such individuals could however either remain healthy or only ever progress to a mild asymptomatic stage. Risk models for complex diseases therefore aim to accurately predict risk by incorporating multiple alleles and or environmental risk factors.

A common method for describing the accuracy of a risk model is to calculate the area under the receiver operating characteristic (ROC) curve (AUC), the ROC being a plot of all possible [sensitivity, specificity] pairs for the model (Figure 1). The AUC can theoretically take values between 0 and 1, but in practice varies from 0.5 – 1. A score of 1 means perfect accuracy, whereas a score of 0.5 indicates the predictive ability of a model is equivalent to random chance, or zero accuracy. A model with a score between 0.5 and 1.0 therefore has greater ability than chance to discriminate between cases and controls. It has been suggested that an AUC >0.75 is acceptable and >0.9 is excellent.<sup>66</sup>

Existing risk models for AMD predict either the risk of developing AMD or of progressing from the early and intermediate stages to advanced disease.<sup>66</sup> Models incorporating only genetic information have achieved AUCs >0.8,<sup>67, 68</sup> and models combining both genetic and environmental risk factors have reported AUCs >0.9.<sup>69-71</sup> Interestingly, a model which only included environmental risk factors predicted the risk of developing advanced AMD with a similar AUC of 0.88,<sup>72</sup> leading some to question the usefulness of genetic data in predictive models.<sup>73</sup> Baseline macular phenotype in particular is a strong predictor of AMD progression. Whereas some groups have shown improved risk model accuracy for disease progression when genotype is included with fundus phenotype,<sup>69, 70</sup> a

228 recent study found only a small addition to predictive power.<sup>74</sup> Future studies looking at which  
229 genetic variants associate specifically with progression of AMD may be useful.

230 While the AUC broadly measures the accuracy of a model to distinguish between cases and controls,  
231 additional factors need to be considered when evaluating a model's ability to estimate risk for  
232 individuals. One method is to use the reclassification approach, which classifies individuals into risk  
233 strata. In a worked example, Jakobsdottir et al applied a genetic risk model for AMD with an AUC of  
234 0.79 to a theoretical population with an AMD prevalence of 5.5% (corresponding approximately to  
235 AMD prevalence in patients older than 65 years).<sup>75</sup> For a sensitivity of 74% and specificity of 31%, the  
236 model classified individuals with >4% risk of AMD as cases ('high risk') and those with <4% risk as  
237 controls ('low risk'). The corresponding positive predictive value was only 12%, meaning that 88% of  
238 those patients classified as 'high risk' should actually have been in the 'low risk' group. The authors  
239 also demonstrated how the model's predictive ability is heavily influenced by disease prevalence,  
240 which is highly age-dependent for AMD. Applying their model with the same sensitivity and  
241 specificity to a population with a 15% AMD prevalence (the approximate prevalence for patents  
242 older than 80 years) classified individuals as greater than 10% risk (cases) or less than 10% risk  
243 (controls) of AMD, with an improved positive predictive value of 30%.<sup>75</sup>

244 As illustrated by the example above, a risk model with a seemingly acceptable AUC may therefore  
245 not be useful clinically as a predictor of individual risk. In addition, some genetic risk variants  
246 discovered in one population may not be as important in others. To date the majority of AMD  
247 genetic associations have been studied in populations of European ancestry. The 19 risk loci  
248 discovered by the AMD Gene Consortium in a non-Amish Caucasian population appear to account  
249 for a lower proportion of AMD in Amish individuals, and a rare *CFH* variant (P503A) associated with  
250 AMD in the Amish population was absent in non-Amish cases and controls.<sup>42,55</sup> The common *CFH*  
251 Y402H risk variant is present in ~30% of Utah residents of Northern and Western European ancestry,  
252 but only ~5% of Japanese and Chinese individuals.<sup>76</sup> A recent study showed both the *CFH* Y402H and

*ARMS2* A69S variants to be associated with AMD in European Americans but not in African Americans, Mexican Americans or Singaporeans.<sup>77</sup> Furthermore, in another study the common *ARMS2* A69S variant was associated with increased risk of AMD in non-Hispanic whites and Mexican-Americans but was found to be protective in non-Hispanic black individuals.<sup>78</sup> This implies that differing genetic loci underlie AMD in different populations and predictive risk models should account for these ethnic variations accordingly.

Despite the limitations of predictive testing in AMD a number of commercial companies now provide genetic AMD tests. Improved accuracy of these tests could in the future aid the detection of high risk individuals who may benefit from early preventive measures. However, there is currently no evidence that changes to the management of such patients beyond current practice is beneficial. For these reasons, the current recommendations from the American Academy of Ophthalmology (AAO) include avoidance of routine genetic testing for complex disorders like AMD, until prospective clinical trials have shown specific surveillance or treatment strategies to be of benefit.<sup>79</sup>

#### ***Pharmacogenetics and AMD***

Another potential use for genetic testing is to identify which AMD patients may respond best to specific treatments. The Age-Related Eye Disease Study (AREDS) antioxidant and zinc formulation is the only therapeutic intervention that has been shown prospectively to significantly reduce the risk of progression to advanced AMD.<sup>80</sup> Genetic testing to guide preventive treatment with the AREDS formulation has proved controversial. Awh et al recently published retrospective analyses on patients from the AREDS trial, reporting that certain *CFH* and *ARMS2* genotypes were associated with potentially harmful responses to dietary antioxidant and zinc supplementation.<sup>81, 82</sup> The authors therefore concluded that favourable outcomes may be achieved by assigning nutritional supplementation based on *CFH* and *ARMS2* genotype. Subsequent analyses by the original AREDS investigators however found the AREDS formulation to be beneficial for all genotypes, as well as pointing out statistical errors made by Awh et al.<sup>83, 84</sup> Other studies have shown the effectiveness of

nutritional supplementation to differ by genotype, but no harmful effects were observed.<sup>85, 86</sup> Prospective clinical trials are needed to more definitively address this issue but at present there is insufficient evidence to support genetic testing prior to recommending AREDS nutritional supplementation.<sup>87, 88</sup>

A number of studies have also examined whether AMD-associated risk variants and VEGF-related gene polymorphisms affect response to anti-VEGF therapy in nvAMD. Although the majority of patients do well with anti-VEGF treatment, 10-15% respond poorly and lose vision.<sup>89</sup> Variation in treatment outcomes is related to clinical characteristics, such as baseline visual acuity and central retinal thickness, and may also be influenced by genetic factors. A single GWAS identified an association between a variant in the *OR52B4* gene and response to anti-VEGF, however this is yet to be replicated.<sup>90</sup> Small retrospective studies have found statistically significant associations between variants in candidate genes, either related to angiogenesis or known to confer AMD risk, and response to anti-VEGF.<sup>91</sup> In contrast, no such genetic associations were observed in the major Comparison of AMD Treatments Trial (CATT) and Inhibit VEGF in Patients with Age-Related CNV Study (IVAN) randomised control trials.<sup>92-96</sup> Recent meta-analyses pooling data from these smaller studies with the major trials have reported positive associations between anti-VEGF treatment response and the *CFH* Y402H and *AMRS2* A69S variants, as well as polymorphisms in *VEGF-A* and *VEGFR-2*, but all acknowledge the need for large prospective trials to validate their findings.<sup>97-100</sup>

#### ***Genetic testing in AMD research***

Routine genetic testing for AMD is therefore currently not advised in clinical practice and further supportive evidence from prospective clinical trials is needed before recommending genetic testing to guide treatment with AREDS nutritional supplementation or anti-VEGF.<sup>79, 87, 88</sup> Genetic testing may however be useful as a research tool, for example to select suitable patients for future clinical trials of novel therapeutics designed to prevent AMD. Restricting patient recruitment to those individuals at highest risk of developing advanced AMD is likely to decrease the sample size requirements for

adequate powering of such studies. Reconsidering the predictive model with an AUC of 0.79 by Jakobsdottir et al discussed earlier, while a positive predictive value of 12-30% may be poor in the clinical setting, it might prove cost-effective to help improve the proportion of participants at high risk of developing AMD in a clinical trial.<sup>75</sup>

Genetic testing could also be useful in therapeutic clinical trials. To date the complement system has been most frequently implicated in AMD and consequently several trials of complement inhibitors have been initiated.<sup>60</sup> AMD is genetically heterogeneous and it is possible that patients with certain risk variants in complement-related genes may respond differentially to complement inhibition. Recently reported findings from the phase II MAHALO trial of lampalizumab, a monoclonal antibody inhibitor of complement factor D, in GA support this concept. Progression of GA lesion size over 18 months follow-up was significantly less in patients treated with monthly intravitreal injections of lampalizumab, however this response was only observed in those patients carrying a common *CFI* risk allele (rs17440077).<sup>101</sup> Results from phase III trials are currently awaited, although preliminary results from one of these phase III trials, Spectri, showed no benefit of lampalizumab therapy overall. It will be interesting to see full results including results in genetic sub-groups.<sup>102</sup>

## **Summary and conclusions**

The proportion of AMD heritability now explained by known genetic risk variants is estimated at approximately 50%. Identification of disease-associated common and rare variants has implicated various biological pathways in AMD pathogenesis. The complement system in particular appears to play an important role and functional studies are beginning to elucidate how complement dysregulation may contribute to AMD. These discoveries have furthermore led to the development of potential novel therapies modulating complement activity. Promising results have now been reported in a phase II trial of the anti-complement factor D antibody lampalizumab in a genetic subgroup,<sup>101</sup> (although early results from the phase III Spectri trial showed no benefit overall),<sup>102</sup> and also in a phase II trial inhibiting C3 in AMD patients.<sup>103</sup> Further work is needed to uncover the

remaining heritable component of AMD and better understand how genetic and environmental factors interact to cause disease.

An improved understanding of AMD genetics will also aid the development of risk models that can more accurately predict disease occurrence and progression. It is possible that such predictive tests may guide AMD patient management in the future if effective preventive therapies and pharmacogenetic associations are discovered, although for now there is insufficient evidence to recommend genetic testing in clinical practice.<sup>79, 87, 88</sup> Genotype-restricted sampling for clinical trials however may help accelerate progress in translational AMD research.

## REFERENCES

1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE *et al.* Risk factors for age-related macular degeneration: Pooled findings from three continents. *Ophthalmology* 2001; **108**: 697-704.
2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY *et al.* Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob. Health.* 2014; **2**: e106-16.
3. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. *Annu. Rev. Genomics Hum. Genet.* 2014; **15**: 151-171.
4. Mullins RF, Warwick AN, Sohn EH, Lotery AJ. From Compliment to Insult- Genetics of the Complement System in Physiology and Disease in the Human Retina. *Hum. Mol. Genet.* 2017;.
5. Sobrin L, Seddon JM. Nature and nurture- genes and environment- predict onset and progression of macular degeneration. *Prog. Retin. Eye Res.* 2014; **40**: 1-15.
6. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. *Am. J. Ophthalmol.* 1997; **123**: 199-206.
7. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. *Arch. Ophthalmol.* 2005; **123**: 321-327.
8. Seddon JM, Afshari MA, Sharma S, Bernstein PS, Chong S, Hutchinson A *et al.* Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy. *Ophthalmology* 2001; **108**: 2060-2067.
9. Ayyagari R, Zhang K, Hutchinson A, Yu Z, Swaroop A, Kakuk LE *et al.* Evaluation of the ELOVL4 gene in patients with age-related macular degeneration. *Ophthalmic Genet.* 2001; **22**: 233-239.

361 10. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular  
362 degeneration: a review of progress to date. *Surv. Ophthalmol.* 2006; **51**: 316-363.

363 11. De La Paz MA, Pericak-Vance MA, Lennon F, Haines JL, Seddon JM. Exclusion of TIMP3 as a  
364 candidate locus in age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 1997; **38**: 1060-  
365 1065.

366 12. Fisher SA, Abecasis GR, Yashar BM, Zarepari S, Swaroop A, Iyengar SK *et al.* Meta-analysis of  
367 genome scans of age-related macular degeneration. *Hum. Mol. Genet.* 2005; **14**: 2257-2264.

368 13. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P *et al.* Complement factor H  
369 variant increases the risk of age-related macular degeneration. *Science* 2005; **308**: 419-421.

370 14. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LJ *et al.* A common  
371 haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-  
372 related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 2005; **102**: 7227-7232.

373 15. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H  
374 polymorphism and age-related macular degeneration. *Science* 2005; **308**: 421-424.

375 16. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C *et al.* Complement factor H polymorphism  
376 in age-related macular degeneration. *Science* 2005; **308**: 385-389.

377 17. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K *et al.* Variation in factor B (BF) and  
378 complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat.*  
379 *Genet.* 2006; **38**: 458-462.

380 18. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H *et al.* Complement C3 variant and  
381 the risk of age-related macular degeneration. *N. Engl. J. Med.* 2007; **357**: 553-561.

382 19. Dinu V, Miller PL, Zhao H. Evidence for association between multiple complement pathway genes  
383 and AMD. *Genet. Epidemiol.* 2007; **31**: 224-237.

384 20. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near  
385 complement factor I is associated with risk of advanced AMD. *Eur. J. Hum. Genet.* 2009; **17**: 100-104.

386 21. Ennis S, Jomary C, Mullins R, Cree A, Chen X, Macleod A *et al.* Association between the SERPING1  
387 gene and age-related macular degeneration: a two-stage case-control study. *Lancet* 2008; **372**:  
388 1828-1834.

389 22. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR *et al.* The pivotal role of  
390 the complement system in aging and age-related macular degeneration: hypothesis re-visited. *Prog.*  
391 *Retin. Eye Res.* 2010; **29**: 95-112.

392 23. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory  
393 processes in Drusen formation and age related macular degeneration. *Exp. Eye Res.* 2001; **73**: 887-  
394 896.

395 24. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H *et al.* Drusen proteome analysis: an  
396 approach to the etiology of age-related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 2002;  
397 **99**: 14682-14687.

398 25. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related  
399 macular degeneration contain proteins common to extracellular deposits associated with  
400 atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB J.* 2000; **14**: 835-846.

401 26. Warwick A, Khandhadia S, Ennis S, Lotery A. Age-Related Macular Degeneration: A Disease of  
402 Systemic or Local Complement Dysregulation? *J. Clin. Med.* 2014; **3**: 1234-1257.

27. Bombback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L *et al.* Eculizumab for dense deposit disease and C3 glomerulonephritis. *Clin. J. Am. Soc. Nephrol.* 2012; **7**: 748-756.

28. McAvoy CE, Silvestri G. Retinal changes associated with type 2 glomerulonephritis. *Eye (Lond)* 2005; **19**: 985-989.

29. Khandhadia S, Hakobyan S, Heng LZ, Gibson J, Adams DH, Alexander GJ *et al.* Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation. *Ophthalmology* 2013; **120**: 1612-1618.

30. Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP *et al.* Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. *Proc. Natl. Acad. Sci. U. S. A.* 2011; **108**: 8761-8766.

31. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. *Proc. Natl. Acad. Sci. U. S. A.* 2006; **103**: 17456-17461.

32. Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN *et al.* Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. *J. Biol. Chem.* 2010; **285**: 30192-30202.

33. Kelly U, Yu L, Kumar P, Ding JD, Jiang H, Hageman GS *et al.* Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. *J. Immunol.* 2010; **185**: 5486-5494.

34. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P *et al.* Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. *Nature* 2011; **478**: 76-81.

35. Nan R, Farabella I, Schumacher FF, Miller A, Gor J, Martin AC *et al.* Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration. *J. Mol. Biol.* 2011; **408**: 714-735.

36. Mullins RF, Schoo DP, Sohn EH, Flamme-Wiese MJ, Workamelahu G, Johnston RM *et al.* The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. *Am. J. Pathol.* 2014; **184**: 3142-3153.

37. Mullins RF, Dewald AD, Streb LM, Wang K, Kuehn MH, Stone EM. Elevated membrane attack complex in human choroid with high risk complement factor H genotypes. *Exp. Eye Res.* 2011; **93**: 565-567.

38. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ *et al.* A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. *Science* 2006; **314**: 992-993.

39. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. *Am. J. Hum. Genet.* 2005; **77**: 389-407.

40. Stanton CM, Chalmers KJ, Wright AF. The chromosome 10q26 susceptibility locus in age-related macular degeneration. *Adv. Exp. Med. Biol.* 2012; **723**: 365-370.

41. Grassmann F, Heid IM, Weber BH, International AMD Genomics Consortium (IAMGDC). Recombinant Haplotypes Narrow the ARMS2/HTRA1 Association Signal for Age-Related Macular Degeneration. *Genetics* 2017; **205**: 919-924.

42. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G *et al.* Seven new loci associated with age-related macular degeneration. *Nat. Genet.* 2013; **45**: 433-9, 439e1-2.



445 43. Yu Y, Bhangale TR, Fagerness J, Ripke S, Thorleifsson G, Tan PL *et al.* Common variants near  
446 FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. *Hum.*  
447 *Mol. Genet.* 2011; **20**: 3699-3709.

448 44. Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL *et al.* A large genome-  
449 wide association study of age-related macular degeneration highlights contributions of rare and  
450 common variants. *Nat. Genet.* 2016; **48**: 134-143.

451 45. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH *et al.* Missing heritability and strategies  
452 for finding the underlying causes of complex disease. *Nat. Rev. Genet.* 2010; **11**: 446-450.

453 46. Gibson G. Rare and common variants: twenty arguments. *Nat. Rev. Genet.* 2012; **13**: 135-145.

454 47. Sobrin L, Maller JB, Neale BM, Reynolds RC, Fagerness JA, Daly MJ *et al.* Genetic profile for five  
455 common variants associated with age-related macular degeneration in densely affected families: a  
456 novel analytic approach. *Eur. J. Hum. Genet.* 2010; **18**: 496-501.

457 48. Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S *et al.* A rare penetrant mutation in  
458 CFH confers high risk of age-related macular degeneration. *Nat. Genet.* 2011; **43**: 1232-1236.

459 49. Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S *et al.* Rare variants in CFI, C3 and  
460 C9 are associated with high risk of advanced age-related macular degeneration. *Nat. Genet.* 2013;  
461 **45**: 1366-1370.

462 50. van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, Mohlin FC *et al.* A functional variant in  
463 the CFI gene confers a high risk of age-related macular degeneration. *Nat. Genet.* 2013; **45**: 813-817.

464 51. Zhan X, Larson DE, Wang C, Koboldt DC, Sergeev YV, Fulton RS *et al.* Identification of a rare  
465 coding variant in complement 3 associated with age-related macular degeneration. *Nat. Genet.*  
466 2013; **45**: 1375-1379.

467 52. Helgason H, Sulem P, Duvvari MR, Luo H, Thorleifsson G, Stefansson H *et al.* A rare  
468 nonsynonymous sequence variant in C3 is associated with high risk of age-related macular  
469 degeneration. *Nat. Genet.* 2013; **45**: 1371-1374.

470 53. Duvvari MR, van de Ven JP, Geerlings MJ, Saksens NT, Bakker B, Henkes A *et al.* Whole Exome  
471 Sequencing in Patients with the Cuticular Drusen Subtype of Age-Related Macular Degeneration.  
472 *PLoS One* 2016; **11**: e0152047.

473 54. Geerlings MJ, Kremlitzka M, Bakker B, Nilsson SC, Saksens NT, Lechanteur YT *et al.* The Functional  
474 Effect of Rare Variants in Complement Genes on C3b Degradation in Patients With Age-Related  
475 Macular Degeneration. *JAMA Ophthalmol.* 2017; **135**: 39-46.

476 55. Hoffman JD, Cooke Bailey JN, D'Aoust L, Cade W, Ayala-Haedo J, Fuzzell D *et al.* Rare complement  
477 factor H variant associated with age-related macular degeneration in the Amish. *Invest. Ophthalmol.*  
478 *Vis. Sci.* 2014; **55**: 4455-4460.

479 56. Pras E, Kristal D, Shoshany N, Volodarsky D, Vulih I, Celniker G *et al.* Rare genetic variants in  
480 Tunisian Jewish patients suffering from age-related macular degeneration. *J. Med. Genet.* 2015; **52**:  
481 484-492.

482 57. Ratnapriya R, Zhan X, Fariss RN, Branham KE, Zipprer D, Chakarova CF *et al.* Rare and common  
483 variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration.  
484 *Hum. Mol. Genet.* 2014; **23**: 5827-5837.

485 58. Saksens NT, Geerlings MJ, Bakker B, Schick T, Daha MR, Fauser S *et al.* Rare Genetic Variants  
486 Associated With Development of Age-Related Macular Degeneration. *JAMA Ophthalmol.* 2016; **134**:  
487 287-293.

59. Yu Y, Triebwasser MP, Wong EK, Schramm EC, Thomas B, Reynolds R *et al.* Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. *Hum. Mol. Genet.* 2014; **23**: 5283-5293.

60. Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. *Mol. Immunol.* 2017; **84**: 65-76.

61. Triebwasser MP, Roberson ED, Yu Y, Schramm EC, Wagner EK, Raychaudhuri S *et al.* Rare Variants in the Functional Domains of Complement Factor H Are Associated With Age-Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2015; **56**: 6873-6878.

62. Wagner EK, Raychaudhuri S, Villalonga MB, Java A, Triebwasser MP, Daly MJ *et al.* Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD. *Sci. Rep.* 2016; **6**: 31531.

63. Ferrara D, Seddon JM. Phenotypic Characterization of Complement Factor H R1210C Rare Genetic Variant in Age-Related Macular Degeneration. *JAMA Ophthalmol.* 2015; **133**: 785-791.

64. Kersten E, Geerlings MJ, den Hollander AI, de Jong EK, Fauser S, Peto T *et al.* Phenotype Characteristics of Patients With Age-Related Macular Degeneration Carrying a Rare Variant in the Complement Factor H Gene. *JAMA Ophthalmol.* 2017;.

65. Warwick A, Gibson J, Sood R, Lotery A. A rare penetrant TIMP3 mutation confers relatively late onset choroidal neovascularisation which can mimic age-related macular degeneration. *Eye (Lond)* 2016; **30**: 488-491.

66. Cooke Bailey JN, Hoffman JD, Sardell RJ, Scott WK, Pericak-Vance MA, Haines JL. The Application of Genetic Risk Scores in Age-Related Macular Degeneration: A Review. *J. Clin. Med.* 2016; **5**: 10.3390/jcm5030031.

67. Grassmann F, Fritsche LG, Keilhauer CN, Heid IM, Weber BH. Modelling the genetic risk in age-related macular degeneration. *PLoS One* 2012; **7**: e37979.

68. Hageman GS, Gehrs K, Lejnine S, Bansal AT, Deangelis MM, Guymer RH *et al.* Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. *Hum. Genomics* 2011; **5**: 420-440.

69. Perlee LT, Bansal AT, Gehrs K, Heier JS, Csaky K, Allikmets R *et al.* Inclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophy. *Ophthalmology* 2013; **120**: 1880-1892.

70. Seddon JM, Silver RE, Kwong M, Rosner B. Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. *Invest. Ophthalmol. Vis. Sci.* 2015; **56**: 2192-2202.

71. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. *Ophthalmology* 2011; **118**: 2203-2211.

72. Chiu CJ, Mitchell P, Klein R, Klein BE, Chang ML, Gensler G *et al.* A risk score for the prediction of advanced age-related macular degeneration: development and validation in 2 prospective cohorts. *Ophthalmology* 2014; **121**: 1421-1427.

73. Schwartz SG, Hampton BM, Kovach JL, Brantley MA, Jr. Genetics and age-related macular degeneration: a practical review for the clinician. *Clin. Ophthalmol.* 2016; **10**: 1229-1235.

530 74. Ding Y, Liu Y, Yan Q, Fritsche LG, Cook RJ, Clemons T *et al.* Bivariate Analysis of Age-Related  
531 Macular Degeneration Progression Using Genetic Risk Scores. *Genetics* 2017; **206**: 119-133.

532 75. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association  
533 studies: markers with replicated highly significant odds ratios may be poor classifiers. *PLoS Genet.*  
534 2009; **5**: e1000337.

535 76. Kondo N, Bessho H, Honda S, Negi A. Complement factor H Y402H variant and risk of age-related  
536 macular degeneration in Asians: a systematic review and meta-analysis. *Ophthalmology* 2011; **118**:  
537 339-344.

538 77. Restrepo NA, Spencer KL, Goodloe R, Garrett TA, Heiss G, Buzkova P *et al.* Genetic determinants  
539 of age-related macular degeneration in diverse populations from the PAGE study. *Invest.*  
540 *Ophthalmol. Vis. Sci.* 2014; **55**: 6839-6850.

541 78. Spencer KL, Glenn K, Brown-Gentry K, Haines JL, Crawford DC. Population Differences in Genetic  
542 Risk for Age-related Macular Degeneration and Implications for Genetic Testing. *Arch. Ophthalmol.*  
543 2012; **130**: 116-117.

544 79. Stone EM, Aldave AJ, Drack AV, *et al.* Recommendations of the American Academy of  
545 Ophthalmology task force on genetic testing. Available from: [https://www.aao.org/clinical-](https://www.aao.org/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d)  
546 [statement/recommendations-genetic-testing-of-inherited-eye-d](https://www.aao.org/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d). Accessed September 22, 2017.

547 80. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids  
548 for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized  
549 clinical trial. *JAMA* 2013; **309**: 2005-2015.

550 81. Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. CFH and ARMS2 genetic polymorphisms predict  
551 response to antioxidants and zinc in patients with age-related macular degeneration. *Ophthalmology*  
552 2013; **120**: 2317-2323.

553 82. Awh CC, Hawken S, Zanke BW. Treatment response to antioxidants and zinc based on CFH and  
554 ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. *Ophthalmology* 2015; **122**:  
555 162-169.

556 83. Chew EY, Klein ML, Clemons TE, Agron E, Abecasis GR. Genetic testing in persons with age-  
557 related macular degeneration and the use of the AREDS supplements: to test or not to test?  
558 *Ophthalmology* 2015; **122**: 212-215.

559 84. Chew EY, Klein ML, Clemons TE, Agron E, Ratnapriya R, Edwards AO *et al.* No clinically significant  
560 association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS  
561 report number 38. *Ophthalmology* 2014; **121**: 2173-2180.

562 85. Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, Schultz DW *et al.* CFH and  
563 LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular  
564 degeneration. *Ophthalmology* 2008; **115**: 1019-1025.

565 86. Seddon JM, Silver RE, Rosner B. Response to AREDS supplements according to genetic factors:  
566 survival analysis approach using the eye as the unit of analysis. *Br. J. Ophthalmol.* 2016; **100**: 1731-  
567 1737.

568 87. Csaky KG, Schachat AP, Kaiser PK, Small KW, Heier JS. The Use of Genetic Testing in the  
569 Management of Patients With Age-Related Macular Degeneration. *Journal of VitreoRetinal Diseases*  
570 2017; **1**: 75-78.

571 88. Stone EM. Genetic testing for age-related macular degeneration: not indicated now. *JAMA*  
572 *Ophthalmol.* 2015; **133**: 598-600.

573 89. Tsimbaris MK, Lopez-Galvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological  
574 and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in  
575 Patients with Neovascular AMD. *J. Ophthalmol.* 2016; **2016**: 4367631.

576 90. Riaz M, Lores-Motta L, Richardson AJ, Lu Y, Montgomery G, Omar A *et al.* GWAS study using DNA  
577 pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF  
578 treatment response in age-related macular degeneration. *Sci. Rep.* 2016; **6**: 37924.

579 91. Fauser S, Lambrou GN. Genetic predictive biomarkers of anti-VEGF treatment response in  
580 patients with neovascular age-related macular degeneration. *Surv. Ophthalmol.* 2015; **60**: 138-152.

581 92. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG *et al.* Pharmacogenetics  
582 for genes associated with age-related macular degeneration in the Comparison of AMD Treatments  
583 Trials (CATT). *Ophthalmology* 2013; **120**: 593-599.

584 93. Hagstrom SA, Ying GS, Pauer GJ, Huang J, Maguire MG, Martin DF *et al.* Endothelial PAS domain-  
585 containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the  
586 comparison of AMD treatments trials (CATT). *Ophthalmology* 2014; **121**: 1663-4.e1.

587 94. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG *et al.* VEGFA and  
588 VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy:  
589 comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol.* 2014;  
590 **132**: 521-527.

591 95. Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA *et al.* Pharmacogenetic  
592 associations with vascular endothelial growth factor inhibition in participants with neovascular age-  
593 related macular degeneration in the IVAN Study. *Ophthalmology* 2013; **120**: 2637-2643.

594 96. Hagstrom SA, Ying GS, Maguire MG, Martin DF, CATT Research Group, Gibson J *et al.* VEGFR2  
595 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-  
596 Related Macular Degeneration. *Ophthalmology* 2015; **122**: 1563-1568.

597 97. Hong N, Shen Y, Yu CY, Wang SQ, Tong JP. Association of the polymorphism Y402H in the CFH  
598 gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic  
599 review and meta-analysis. *Acta Ophthalmol.* 2016; **94**: 334-345.

600 98. Hu Z, Xie P, Ding Y, Yuan D, Liu Q. Association between variants A69S in ARMS2 gene and  
601 response to treatment of exudative AMD: a meta-analysis. *Br. J. Ophthalmol.* 2015; **99**: 593-598.

602 99. Wu M, Xiong H, Xu Y, Xiong X, Zou H, Zheng M *et al.* Association between VEGF-A and VEGFR-2  
603 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-  
604 analysis. *Br. J. Ophthalmol.* 2017; **101**: 976-984.

605 100. Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y. Pharmacogenetics of Complement Factor H  
606 Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.  
607 *Sci. Rep.* 2015; **5**: 14517.

608 101. Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A *et al.* Targeting factor D of the  
609 alternative complement pathway reduces geographic atrophy progression secondary to age-related  
610 macular degeneration. *Sci. Transl. Med.* 2017; **9**: 10.1126/scitranslmed.aaf1443.

611 102. Roche. Roche provides update on first lapaizumab phase III study for geographic atrophy, an  
612 advanced form of age-related macular degeneration. Available from:  
613 <https://www.roche.com/media/store/releases/med-cor-2017-09-08b.htm>. Accessed September 22,  
614 2017.  
615

103. Apellis. Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration. Available from: <http://apellis.com/pdfs/Press%20Release%20FILLY%2012%20Month%20Results%20FINAL%20FINAL%20170823.pdf>. Accessed September 22, 2017.

## TITLES AND LEGENDS TO FIGURES

**Figure 1.** An example receiver operating characteristic (ROC) curve. The solid black line represents an area under the ROC (AUC) of 0.5, random chance. The dashed black line indicates an AUC of 1.0, a perfect model. The dotted grey line represents a ROC curve with an AUC between 0.5 and 1.0, as may be generated by a predictive risk model. Specificity decreases with increasing sensitivity.

1     **Genetics and genetic testing for age-related macular degeneration**

2     Alasdair Warwick MBBS BSc<sup>1</sup>

3     Andrew Lotery MD FRCOphth<sup>2, 3 \*</sup>

4     <sup>1</sup>Moorfields Eye Hospital, 162 City Road, London EC1V 2PD

5     <sup>2</sup>Faculty of Medicine, Clinical and Experimental Sciences, University of Southampton, Southampton  
6     SO16 6YD, UK

7     \*Author to whom correspondence should be addressed; Email: [a.j.lotery@soton.ac.uk](mailto:a.j.lotery@soton.ac.uk); Tel: +44-238-  
8     079-5049; Fax: +44-238-079-4542

9     Conflict of interest: none to declare

10    Funding: none

11    Running title: Genetics and genetic testing for age-related macular degeneration

12

13

14    Word count: 3735

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31    **Abstract**

32    Considerable advances have been made in our understanding of age-related macular degeneration  
33    (AMD) genetics over the past decade. The genetic associations discovered to date are estimated to  
34    account for approximately half of AMD heritability and functional studies of these variants have  
35    revealed new insights into disease pathogenesis, leading to the development of potential novel  
36    therapies. There is furthermore growing interest in genetic testing for predicting an individual's risk  
37    of AMD and offering personalised preventive or therapeutic treatments. We review the progress  
38    made so far in AMD genetics and discuss the possible applications for genetic testing.

39

40

41

42

43

44

45

46

47

48

49

50

51

52

## 53     **Introduction**

54     Age-related macular degeneration (AMD) is the commonest cause of blindness in the developed  
55     world, affecting 5% of those aged >75 years old and an estimated 150 million people worldwide.<sup>1, 2</sup>

56     Disease onset is in later life, typically after the age of 60 years, and is characterised clinically by  
57     retinal pigmentary change and the appearance of drusen at the macula. Central vision may  
58     subsequently decline either gradually with progressive geographic retinal atrophy (GA), or acutely  
59     due to retinal haemorrhage and fluid exudation from choroidal neovascularisation (CNV) if  
60     neovascular AMD (nvAMD) develops. While the latter may now be effectively treated with  
61     intravitreal anti-vascular endothelial growth factor (VEGF) injections, there is currently no therapy  
62     for GA available in clinical practice.<sup>3</sup>

63     Over the past decade considerable progress has been made in elucidating the genetic architecture of  
64     AMD. The discovery of multiple genetic associations and studies of their downstream functional  
65     consequences has helped reveal new underlying pathophysiological mechanisms in AMD, affording  
66     the potential to identify molecular targets for novel therapies. The complement pathway in  
67     particular, an important component of the innate immune system, has been consistently  
68     implicated.<sup>4</sup> Furthermore, there is growing interest in genetic testing to predict either an individual's  
69     risk of developing AMD or how well they will respond to treatment. Ultimately this could mean that  
70     in the future patients are offered personalised preventive or therapeutic treatments, tailored to  
71     their individual genetic makeup. In this review, we summarise the current literature and possible  
72     future directions for AMD genetics and genetic testing.

## 73     **Genetics of AMD**

74     AMD is a complex disease with multiple environmental and genetic risk factors. The most  
75     consistently associated environmental risk factors are age and smoking, although gender, race,  
76     cardiovascular disease and diet have also been implicated.<sup>5</sup> Evidence for a genetic component was  
77     supported by family aggregation studies and twin studies. In family aggregation studies, the



78 prevalence of AMD was higher in first degree relatives of AMD patients (23.7%) compared with  
79 relatives of controls (11.6%), with an odds ratio (OR) of 2.4.<sup>6</sup> By comparing disease concordance  
80 rates between monozygotic and dizygotic twins, the heritability of early and advanced AMD has  
81 been estimated at 46% and 71% respectively, implying 46-71% of AMD variation may be explained  
82 by genetic factors.<sup>7</sup>

83 In early efforts to explore AMD genetics, association studies were performed for candidate genes  
84 known to cause Mendelian macular diseases such as Best's disease, Stargardt's disease and Sorsby's  
85 fundus dystrophy. However, no consistent significant associations were made.<sup>8-11</sup> Other groups  
86 undertook genetic linkage studies of patient families to identify genomic regions containing  
87 susceptibility loci for AMD. A meta-analysis of these results showed the most replicated findings  
88 were on chromosomes 1q25-31 and 10q26.<sup>12</sup> Their importance was then validated by subsequent  
89 findings of specific AMD-associated common genetic variants at these two loci – the complement  
90 factor H (*CFH*) gene on chromosome 1 and the age-related maculopathy susceptibility 2/HtrA serine  
91 peptidase (*ARMS2/HTRA1*) genes on chromosome 10.

## 92 ***Common variants***

93 Technological advancements enabling the analysis of whole genomes, rather than individual genes,  
94 have greatly accelerated the discovery of new genetic associations with common complex genetic  
95 diseases such as AMD. Genome-wide association studies (GWAS) examine a genome-wide set of  
96 genetic variants, typically single nucleotide polymorphisms (SNPs), for associations with the disease  
97 of interest. Whereas genetic linkage studies are effective for investigating high penetrance single  
98 gene defects underlying rare monogenic disorders, GWASs are better able to detect low penetrance  
99 common genetic variants (with a minor allele frequency (MAF) >5%) associated with complex  
100 genetic diseases.

101 In 2005 landmark studies associated a common polymorphism (Tyr402His, or Y402H) in the *CFH*  
102 gene on chromosome 1 with AMD.<sup>13-16</sup> One of these was the first GWAS performed for AMD,

showing that the Y402H risk allele had a large effect size (4.6 and 7.4 increased likelihood of AMD in heterozygous and homozygous individuals respectively).<sup>16</sup> Of note this was the first successful GWAS of a 'complex disease' i.e. one with both genetic and environmental factors contributing significantly to disease. As such it represented a major success for genetic approaches to studying common diseases. Subsequent GWASs and candidate gene studies have since associated several other common variants in complement-related genes with AMD, including *C2/CFB*,<sup>17</sup> *C3*,<sup>18</sup> *C7*,<sup>19</sup> *CFI*<sup>20</sup> and *SERPINE1*.<sup>21</sup>

The complement cascade encompasses a family of more than 30 circulating proteins and their regulators which form an important part of the innate immune system. Activation of the complement cascade ultimately results in formation of the membrane attack complex (MAC), which induces cell lysis. While the liver is the major source of systemic complement, retinal cells synthesise their own complement<sup>22</sup> and complement proteins have been detected in drusen from human eyes.<sup>23-25</sup> Raised systemic levels of complement have also been reported in AMD patients versus controls<sup>26</sup> and interestingly patients with dense deposit disease, a renal condition associated with systemic complement dysregulation and glomerular C3 deposition, often develop drusen.<sup>27, 28</sup> However locally produced, rather than systemic, complement appears likely to be more important in AMD.<sup>26, 29</sup>

Chronic intraocular complement-mediated inflammation in genetically susceptible individuals exposed to environmental triggers, such as cigarette smoke and oxidative stress, may contribute to the progressive retinal changes observed in AMD. While the functional relevance of most common AMD-associated genetic variants remains unknown, a common missense polymorphism in *C3* has been shown to result in reduced binding to CFH, a plasma regulator of complement, and increased activity of the alternative complement pathway.<sup>30</sup> Furthermore, a number of studies have looked at the functional effects of the non-synonymous *CFH* Y402H polymorphism. The minor allele, encoding a histidine amino acid at residue 402 of the CFH protein, alters its affinity for CRP,<sup>31</sup>

glycosaminoglycans in Bruch's membrane,<sup>32, 33</sup> malondialdehyde<sup>34</sup> and zinc.<sup>35</sup> These changes are thought to decrease its ability to regulate complement. Reduced complement regulation may lead to increased MAC deposition and choroidal endothelial cell death, impairing the ability of the choriocapillaris to remove debris and allowing the accumulation of waste products in drusen.<sup>4</sup> In support of this theory, eyes homozygous for the *CFH* Y402H risk variant have thinner choroids<sup>36</sup> and increased MAC deposition<sup>37</sup> at the choriocapillaris compared with eyes with low-risk *CFH* genotypes.

Genes not involved in the complement pathway have also been associated with AMD. The *ARMS2/HTRA1* locus on chromosome 10q26 has been strongly associated, risk alleles conferring an OR of 5.0 and a population attributable risk up to 57%.<sup>38, 39</sup> As both genes at this region are in strong linkage disequilibrium with each other and both harbour functional variants which could plausibly be relevant to AMD, dissecting out which is responsible for the observed association with AMD has proved challenging.<sup>40</sup> Recently however, analysis of the largest data set for AMD genetics to date suggested that genetic variants at *ARMS2*, but not *HTRA1*, are responsible for AMD susceptibility at the 10q26 locus.<sup>41</sup> Further functional analysis of *ARMS2* is required to understand its role in AMD pathogenesis. Other non-complement associations with AMD include genes implicated in angiogenesis (*TGFBR1*, *VEGFA*), the extracellular collagen matrix (*COL10A1*, *COL8A1*), the high density lipoprotein cholesterol pathway (*APOE*, *CETP*, *LIPC*) and immune regulation (*PILRB*).<sup>42-44</sup>

#### **Rare variants**

In 2013 the AMD Gene Consortium published the largest GWAS for AMD conducted up until that time, evaluating >2.4 million SNPs in >17,100 cases and >60,000 controls. However they estimated that only 15-65% of AMD heritability was explained by the 19 loci discovered.<sup>42</sup> Several theories seeking to explain missing heritability exist, including gene-environment interactions, gene-gene interactions, epigenetics, copy number variation and rare variants.<sup>45</sup> In particular, the focus of genetic research for complex diseases in general has shifted toward identifying low-frequency (MAF 1-5%) and rare variants (MAF≤1%) with relatively large effect sizes.<sup>46</sup> Furthermore, a recent

simulation study demonstrated that the clustering of AMD in densely affected families was insufficiently explained by the genotypic load of common genetic risk variants and that rare variants may be more important.<sup>47</sup>

Various approaches have been successful in discovering new rare genetic variants associated with AMD. Next generation sequencing technology can be used to comprehensively analyse variation within candidate genes between cases and controls. The first rare variant to be associated with AMD, *CFH* R1210C, was identified in this way.<sup>48</sup> It demonstrated high penetrance (present in 40 cases versus 1 control,  $p = 7.0 \times 10^{-6}$ , OR 18.8) and was associated with earlier onset of disease. Similar studies have also identified rare variants in *CFI*, *C3* and *C9*.<sup>49-51</sup> Whole exome or whole genome sequencing is expensive to carry out in large numbers but has been performed in an Icelandic case-control cohort<sup>52</sup> as well as in large AMD families, thought to be enriched for rare variants.<sup>53-59</sup> In 2016 the International AMD Genomics Consortium (IAMGCG) identified 52 independently associated common and rare variants distributed across 34 loci.<sup>44</sup> The group performed a GWAS using an exome chip, customised to analyse >12 million variants (including >163,700 directly genotyped, mostly rare, protein-altering variants) in >16,100 patients and >17,800 controls. This is the largest study of AMD genetics performed to date, more than doubling the number of known associated variants and identifying the first variant specific to one advanced AMD phenotype (*MMP9* and nvAMD). Rare variants were discovered in *CFH* and *CFI*, as well as the non-complement genes *TIMP3* and *SLC16A8*.<sup>44</sup>

Compared with common variants, highly penetrant rare variants often have clearer functional effects.<sup>60</sup> For example, in a large advanced AMD cohort rare *CFH* variants tended to be located in functional domains and resulted in low CFH serum levels.<sup>61</sup> Rare variants in *CFI*, another regulator of the complement system, have also been associated with decreased serum CFI levels<sup>54</sup> and carriers of rare variants in both *CFH* and *CFI* have impaired ability to regulate complement activation.<sup>54, 59</sup> Furthermore, the rare *C3* Lys155Gln variant has been shown to impair C3b regulation by CFI with

bound *CFH*.<sup>49</sup> Overall these findings support the hypothesis that increased complement activity may contribute to AMD pathogenesis.

Carriers of rare variants appear to have differing phenotypes compared with non-carriers. A number of studies have shown rare variants to be associated with earlier onset of advanced AMD.<sup>48, 58, 59, 62, 63</sup> Carriers of rare *CFH* variants have increased drusen load, are more likely to have extramacular drusen, drusen nasal to the optic disc and crystalline or calcified drusen.<sup>62-64</sup> In addition, rare variants in *CFH*, *CFI*, *C9* and *C3* have been more frequently observed in patients with GA than those with nvAMD.<sup>58, 63</sup> Interestingly a rare missense mutation in *TIMP3* (C1113G), identified by the IAMDGC, is associated with earlier age of disease onset (average age 65 years) and bilateral CNV.<sup>65</sup> Other mutations in *TIMP3* cause Sorsby's fundus dystrophy, an autosomal dominant fundus dystrophy characterised by a similar clinical phenotype to AMD, although typically age of onset is in the fourth decade of life. Further genotype-phenotype correlations are needed to determine whether the phenotype associated with this mutation more closely resembles AMD or Sorsby's fundus dystrophy. The IAMDGC estimate that the 52 currently known variants account for approximately half the genomic heritability of AMD.<sup>44</sup> Despite this significant progress there is still therefore a large portion of missing heritability. The IAMDGC highlight the need for very large sample sizes and extensive genome coverage in population studies looking for novel rare variants in complex diseases. Future studies looking at other potential sources of missing heritability and functional studies of known associated variants are also needed.

### **Genetic testing for AMD**

As the list of known AMD-associated genetic variants continues to grow, so too does interest in developing predictive risk models incorporating these alleles. The ability to accurately predict a person's risk of developing AMD would be an important step towards personalised medicine, allowing appropriate preventive measures to be taken in high-risk individuals. Pharmacogenetic testing could furthermore help identify which AMD patients are most likely to benefit from certain

treatments. For example, it is conceivable that novel therapies modulating the complement system may be most effective in patients harbouring complement-related risk alleles.

***Genetic risk models for AMD***

In contrast to rare monogenic disorders, complex genetic diseases such as AMD are associated with multiple environmental and genetic risk factors. Possession of an allele known to be associated with disease increases an individual's risk of developing the condition and possessing multiple risk alleles or exposure to certain environmental triggers may further increase this risk. Such individuals could however either remain healthy or only ever progress to a mild asymptomatic stage. Risk models for complex diseases therefore aim to accurately predict risk by incorporating multiple alleles and or environmental risk factors.

A common method for describing the accuracy of a risk model is to calculate the area under the receiver operating characteristic (ROC) curve (AUC), the ROC being a plot of all possible [sensitivity, specificity] pairs for the model (Figure 1). The AUC can theoretically take values between 0 and 1, but in practice varies from 0.5 – 1. A score of 1 means perfect accuracy, whereas a score of 0.5 indicates the predictive ability of a model is equivalent to random chance, or zero accuracy. A model with a score between 0.5 and 1.0 therefore has greater ability than chance to discriminate between cases and controls. It has been suggested that an AUC >0.75 is acceptable and >0.9 is excellent.<sup>66</sup>

Existing risk models for AMD predict either the risk of developing AMD or of progressing from the early and intermediate stages to advanced disease.<sup>66</sup> Models incorporating only genetic information have achieved AUCs >0.8,<sup>67, 68</sup> and models combining both genetic and environmental risk factors have reported AUCs >0.9.<sup>69-71</sup> Interestingly, a model which only included environmental risk factors predicted the risk of developing advanced AMD with a similar AUC of 0.88,<sup>72</sup> leading some to question the usefulness of genetic data in predictive models.<sup>73</sup> Baseline macular phenotype in particular is a strong predictor of AMD progression. Whereas some groups have shown improved risk model accuracy for disease progression when genotype is included with fundus phenotype,<sup>69, 70</sup> a

228 recent study found only a small addition to predictive power.<sup>74</sup> Future studies looking at which  
 229 genetic variants associate specifically with progression of AMD may be useful.

230 While the AUC broadly measures the accuracy of a model to distinguish between cases and controls,  
 231 additional factors need to be considered when evaluating a model's ability to estimate risk for  
 232 individuals. One method is to use the reclassification approach, which classifies individuals into risk  
 233 strata. In a worked example, Jakobsdottir et al applied a genetic risk model for AMD with an AUC of  
 234 0.79 to a theoretical population with an AMD prevalence of 5.5% (corresponding approximately to  
 235 AMD prevalence in patients older than 65 years).<sup>75</sup> For a sensitivity of 74% and specificity of 31%, the  
 236 model classified individuals with >4% risk of AMD as cases ('high risk') and those with <4% risk as  
 237 controls ('low risk'). The corresponding positive predictive value was only 12%, meaning that 88% of  
 238 those patients classified as 'high risk' should actually have been in the 'low risk' group. The authors  
 239 also demonstrated how the model's predictive ability is heavily influenced by disease prevalence,  
 240 which is highly age-dependent for AMD. Applying their model with the same sensitivity and  
 241 specificity to a population with a 15% AMD prevalence (the approximate prevalence for patents  
 242 older than 80 years) classified individuals as greater than 10% risk (cases) or less than 10% risk  
 243 (controls) of AMD, with an improved positive predictive value of 30%.<sup>75</sup>

244 As illustrated by the example above, a risk model with a seemingly acceptable AUC may therefore  
 245 not be useful clinically as a predictor of individual risk. In addition, some genetic risk variants  
 246 discovered in one population may not be as important in others. To date the majority of AMD  
 247 genetic associations have been studied in populations of European ancestry. The 19 risk loci  
 248 discovered by the AMD Gene Consortium in a non-Amish Caucasian population appear to account  
 249 for a lower proportion of AMD in Amish individuals, and a rare *CFH* variant (P503A) associated with  
 250 AMD in the Amish population was absent in non-Amish cases and controls.<sup>42,55</sup> The common *CFH*  
 251 Y402H risk variant is present in ~30% of Utah residents of Northern and Western European ancestry,  
 252 but only ~5% of Japanese and Chinese individuals.<sup>76</sup> A recent study showed both the *CFH* Y402H and

*ARMS2* A69S variants to be associated with AMD in European Americans but not in African Americans, Mexican Americans or Singaporeans.<sup>77</sup> Furthermore, in another study the common *ARMS2* A69S variant was associated with increased risk of AMD in non-Hispanic whites and Mexican-Americans but was found to be protective in non-Hispanic black individuals.<sup>78</sup> This implies that differing genetic loci underlie AMD in different populations and predictive risk models should account for these ethnic variations accordingly.

Despite the limitations of predictive testing in AMD a number of commercial companies now provide genetic AMD tests. Improved accuracy of these tests could in the future aid the detection of high risk individuals who may benefit from early preventive measures. However, there is currently no evidence that changes to the management of such patients beyond current practice is beneficial. For these reasons, the current recommendations from the American Academy of Ophthalmology (AAO) include avoidance of routine genetic testing for complex disorders like AMD, until prospective clinical trials have shown specific surveillance or treatment strategies to be of benefit.<sup>79</sup>

#### ***Pharmacogenetics and AMD***

Another potential use for genetic testing is to identify which AMD patients may respond best to specific treatments. The Age-Related Eye Disease Study (AREDS) antioxidant and zinc formulation is the only therapeutic intervention that has been shown prospectively to significantly reduce the risk of progression to advanced AMD.<sup>80</sup> Genetic testing to guide preventive treatment with the AREDS formulation has proved controversial. Awh et al recently published retrospective analyses on patients from the AREDS trial, reporting that certain *CFH* and *ARMS2* genotypes were associated with potentially harmful responses to dietary antioxidant and zinc supplementation.<sup>81, 82</sup> The authors therefore concluded that favourable outcomes may be achieved by assigning nutritional supplementation based on *CFH* and *ARMS2* genotype. Subsequent analyses by the original AREDS investigators however found the AREDS formulation to be beneficial for all genotypes, as well as pointing out statistical errors made by Awh et al.<sup>83, 84</sup> Other studies have shown the effectiveness of



nutritional supplementation to differ by genotype, but no harmful effects were observed.<sup>85, 86</sup> Prospective clinical trials are needed to more definitively address this issue but at present there is insufficient evidence to support genetic testing prior to recommending AREDS nutritional supplementation.<sup>87, 88</sup>

A number of studies have also examined whether AMD-associated risk variants and VEGF-related gene polymorphisms affect response to anti-VEGF therapy in nvAMD. Although the majority of patients do well with anti-VEGF treatment, 10-15% respond poorly and lose vision.<sup>89</sup> Variation in treatment outcomes is related to clinical characteristics, such as baseline visual acuity and central retinal thickness, and may also be influenced by genetic factors. A single GWAS identified an association between a variant in the *OR52B4* gene and response to anti-VEGF, however this is yet to be replicated.<sup>90</sup> Small retrospective studies have found statistically significant associations between variants in candidate genes, either related to angiogenesis or known to confer AMD risk, and response to anti-VEGF.<sup>91</sup> In contrast, no such genetic associations were observed in the major Comparison of AMD Treatments Trial (CATT) and Inhibit VEGF in Patients with Age-Related CNV Study (IVAN) randomised control trials.<sup>92-96</sup> Recent meta-analyses pooling data from these smaller studies with the major trials have reported positive associations between anti-VEGF treatment response and the *CFH* Y402H and *AMRS2* A69S variants, as well as polymorphisms in *VEGF-A* and *VEGFR-2*, but all acknowledge the need for large prospective trials to validate their findings.<sup>97-100</sup>

#### ***Genetic testing in AMD research***

Routine genetic testing for AMD is therefore currently not advised in clinical practice and further supportive evidence from prospective clinical trials is needed before recommending genetic testing to guide treatment with AREDS nutritional supplementation or anti-VEGF.<sup>79, 87, 88</sup> Genetic testing may however be useful as a research tool, for example to select suitable patients for future clinical trials of novel therapeutics designed to prevent AMD. Restricting patient recruitment to those individuals at highest risk of developing advanced AMD is likely to decrease the sample size requirements for

adequate powering of such studies. Reconsidering the predictive model with an AUC of 0.79 by Jakobsdottir et al discussed earlier, while a positive predictive value of 12-30% may be poor in the clinical setting, it might prove cost-effective to help improve the proportion of participants at high risk of developing AMD in a clinical trial.<sup>75</sup>

Genetic testing could also be useful in therapeutic clinical trials. To date the complement system has been most frequently implicated in AMD and consequently several trials of complement inhibitors have been initiated.<sup>60</sup> AMD is genetically heterogeneous and it is possible that patients with certain risk variants in complement-related genes may respond differentially to complement inhibition. Recently reported findings from the phase II MAHALO trial of lampalizumab, a monoclonal antibody inhibitor of complement factor D, in GA support this concept. Progression of GA lesion size over 18 months follow-up was significantly less in patients treated with monthly intravitreal injections of lampalizumab, however this response was only observed in those patients carrying a common *CFI* risk allele (rs17440077).<sup>101</sup> Results from phase III trials are currently awaited, although preliminary results from one of these phase III trials, Spectri, showed no benefit of lampalizumab therapy overall. It will be interesting to see full results including results in genetic sub-groups.<sup>102</sup>

## **Summary and conclusions**

The proportion of AMD heritability now explained by known genetic risk variants is estimated at approximately 50%. Identification of disease-associated common and rare variants has implicated various biological pathways in AMD pathogenesis. The complement system in particular appears to play an important role and functional studies are beginning to elucidate how complement dysregulation may contribute to AMD. These discoveries have furthermore led to the development of potential novel therapies modulating complement activity. Promising results have now been reported in a phase II trial of the anti-complement factor D antibody lampalizumab in a genetic subgroup,<sup>101</sup> (although early results from the phase III Spectri trial showed no benefit overall),<sup>102</sup> and also in a phase II trial inhibiting C3 in AMD patients.<sup>103</sup> Further work is needed to uncover the

remaining heritable component of AMD and better understand how genetic and environmental factors interact to cause disease.

An improved understanding of AMD genetics will also aid the development of risk models that can more accurately predict disease occurrence and progression. It is possible that such predictive tests may guide AMD patient management in the future if effective preventive therapies and pharmacogenetic associations are discovered, although for now there is insufficient evidence to recommend genetic testing in clinical practice.<sup>79, 87, 88</sup> Genotype-restricted sampling for clinical trials however may help accelerate progress in translational AMD research.

## REFERENCES

1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE *et al.* Risk factors for age-related macular degeneration: Pooled findings from three continents. *Ophthalmology* 2001; **108**: 697-704.
2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY *et al.* Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob. Health.* 2014; **2**: e106-16.
3. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. *Annu. Rev. Genomics Hum. Genet.* 2014; **15**: 151-171.
4. Mullins RF, Warwick AN, Sohn EH, Lotery AJ. From Compliment to Insult- Genetics of the Complement System in Physiology and Disease in the Human Retina. *Hum. Mol. Genet.* 2017;.
5. Sobrin L, Seddon JM. Nature and nurture- genes and environment- predict onset and progression of macular degeneration. *Prog. Retin. Eye Res.* 2014; **40**: 1-15.
6. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. *Am. J. Ophthalmol.* 1997; **123**: 199-206.
7. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. *Arch. Ophthalmol.* 2005; **123**: 321-327.
8. Seddon JM, Afshari MA, Sharma S, Bernstein PS, Chong S, Hutchinson A *et al.* Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy. *Ophthalmology* 2001; **108**: 2060-2067.
9. Ayyagari R, Zhang K, Hutchinson A, Yu Z, Swaroop A, Kakuk LE *et al.* Evaluation of the ELOVL4 gene in patients with age-related macular degeneration. *Ophthalmic Genet.* 2001; **22**: 233-239.

361 10. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular  
362 degeneration: a review of progress to date. *Surv. Ophthalmol.* 2006; **51**: 316-363.

363 11. De La Paz MA, Pericak-Vance MA, Lennon F, Haines JL, Seddon JM. Exclusion of TIMP3 as a  
364 candidate locus in age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 1997; **38**: 1060-  
365 1065.

366 12. Fisher SA, Abecasis GR, Yashar BM, Zarepari S, Swaroop A, Iyengar SK *et al.* Meta-analysis of  
367 genome scans of age-related macular degeneration. *Hum. Mol. Genet.* 2005; **14**: 2257-2264.

368 13. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P *et al.* Complement factor H  
369 variant increases the risk of age-related macular degeneration. *Science* 2005; **308**: 419-421.

370 14. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LJ *et al.* A common  
371 haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-  
372 related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 2005; **102**: 7227-7232.

373 15. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H  
374 polymorphism and age-related macular degeneration. *Science* 2005; **308**: 421-424.

375 16. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C *et al.* Complement factor H polymorphism  
376 in age-related macular degeneration. *Science* 2005; **308**: 385-389.

377 17. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K *et al.* Variation in factor B (BF) and  
378 complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat.*  
379 *Genet.* 2006; **38**: 458-462.

380 18. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H *et al.* Complement C3 variant and  
381 the risk of age-related macular degeneration. *N. Engl. J. Med.* 2007; **357**: 553-561.

382 19. Dinu V, Miller PL, Zhao H. Evidence for association between multiple complement pathway genes  
383 and AMD. *Genet. Epidemiol.* 2007; **31**: 224-237.

384 20. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near  
385 complement factor I is associated with risk of advanced AMD. *Eur. J. Hum. Genet.* 2009; **17**: 100-104.

386 21. Ennis S, Jomary C, Mullins R, Cree A, Chen X, Macleod A *et al.* Association between the SERPING1  
387 gene and age-related macular degeneration: a two-stage case-control study. *Lancet* 2008; **372**:  
388 1828-1834.

389 22. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR *et al.* The pivotal role of  
390 the complement system in aging and age-related macular degeneration: hypothesis re-visited. *Prog.*  
391 *Retin. Eye Res.* 2010; **29**: 95-112.

392 23. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory  
393 processes in Drusen formation and age related macular degeneration. *Exp. Eye Res.* 2001; **73**: 887-  
394 896.

395 24. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H *et al.* Drusen proteome analysis: an  
396 approach to the etiology of age-related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 2002;  
397 **99**: 14682-14687.

398 25. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related  
399 macular degeneration contain proteins common to extracellular deposits associated with  
400 atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB J.* 2000; **14**: 835-846.

401 26. Warwick A, Khandhadia S, Ennis S, Lotery A. Age-Related Macular Degeneration: A Disease of  
402 Systemic or Local Complement Dysregulation? *J. Clin. Med.* 2014; **3**: 1234-1257.

403 27. Bombback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L *et al.* Eculizumab for dense deposit  
404 disease and C3 glomerulonephritis. *Clin. J. Am. Soc. Nephrol.* 2012; **7**: 748-756.

405 28. McAvoy CE, Silvestri G. Retinal changes associated with type 2 glomerulonephritis. *Eye (Lond)*  
406 2005; **19**: 985-989.

407 29. Khandhadia S, Hakobyan S, Heng LZ, Gibson J, Adams DH, Alexander GJ *et al.* Age-related macular  
408 degeneration and modification of systemic complement factor H production through liver  
409 transplantation. *Ophthalmology* 2013; **120**: 1612-1618.

410 30. Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP *et al.*  
411 Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic  
412 complement activity and disease risk. *Proc. Natl. Acad. Sci. U. S. A.* 2011; **108**: 8761-8766.

413 31. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals  
414 homozygous for the age-related macular degeneration risk-conferring variant of complement factor  
415 H have elevated levels of CRP in the choroid. *Proc. Natl. Acad. Sci. U. S. A.* 2006; **103**: 17456-17461.

416 32. Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN *et al.* Impaired binding of the  
417 age-related macular degeneration-associated complement factor H 402H allotype to Bruch's  
418 membrane in human retina. *J. Biol. Chem.* 2010; **285**: 30192-30202.

419 33. Kelly U, Yu L, Kumar P, Ding JD, Jiang H, Hageman GS *et al.* Heparan sulfate, including that in  
420 Bruch's membrane, inhibits the complement alternative pathway: implications for age-related  
421 macular degeneration. *J. Immunol.* 2010; **185**: 5486-5494.

422 34. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P *et al.* Complement  
423 factor H binds malondialdehyde epitopes and protects from oxidative stress. *Nature* 2011; **478**: 76-  
424 81.

425 35. Nan R, Farabella I, Schumacher FF, Miller A, Gor J, Martin AC *et al.* Zinc binding to the Tyr402 and  
426 His402 allotypes of complement factor H: possible implications for age-related macular  
427 degeneration. *J. Mol. Biol.* 2011; **408**: 714-735.

428 36. Mullins RF, Schoo DP, Sohn EH, Flamme-Wiese MJ, Workamelahu G, Johnston RM *et al.* The  
429 membrane attack complex in aging human choriocapillaris: relationship to macular degeneration  
430 and choroidal thinning. *Am. J. Pathol.* 2014; **184**: 3142-3153.

431 37. Mullins RF, Dewald AD, Streb LM, Wang K, Kuehn MH, Stone EM. Elevated membrane attack  
432 complex in human choroid with high risk complement factor H genotypes. *Exp. Eye Res.* 2011; **93**:  
433 565-567.

434 38. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ *et al.* A variant of the HTRA1 gene  
435 increases susceptibility to age-related macular degeneration. *Science* 2006; **314**: 992-993.

436 39. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-  
437 related maculopathy on chromosome 10q26. *Am. J. Hum. Genet.* 2005; **77**: 389-407.

438 40. Stanton CM, Chalmers KJ, Wright AF. The chromosome 10q26 susceptibility locus in age-related  
439 macular degeneration. *Adv. Exp. Med. Biol.* 2012; **723**: 365-370.

440 41. Grassmann F, Heid IM, Weber BH, International AMD Genomics Consortium (IAMGDC).  
441 Recombinant Haplotypes Narrow the ARMS2/HTRA1 Association Signal for Age-Related Macular  
442 Degeneration. *Genetics* 2017; **205**: 919-924.

443 42. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G *et al.* Seven new loci associated  
444 with age-related macular degeneration. *Nat. Genet.* 2013; **45**: 433-9, 439e1-2.

445 43. Yu Y, Bhangale TR, Fagerness J, Ripke S, Thorleifsson G, Tan PL *et al.* Common variants near  
446 FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. *Hum.*  
447 *Mol. Genet.* 2011; **20**: 3699-3709.

448 44. Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL *et al.* A large genome-  
449 wide association study of age-related macular degeneration highlights contributions of rare and  
450 common variants. *Nat. Genet.* 2016; **48**: 134-143.

451 45. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH *et al.* Missing heritability and strategies  
452 for finding the underlying causes of complex disease. *Nat. Rev. Genet.* 2010; **11**: 446-450.

453 46. Gibson G. Rare and common variants: twenty arguments. *Nat. Rev. Genet.* 2012; **13**: 135-145.

454 47. Sobrin L, Maller JB, Neale BM, Reynolds RC, Fagerness JA, Daly MJ *et al.* Genetic profile for five  
455 common variants associated with age-related macular degeneration in densely affected families: a  
456 novel analytic approach. *Eur. J. Hum. Genet.* 2010; **18**: 496-501.

457 48. Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S *et al.* A rare penetrant mutation in  
458 CFH confers high risk of age-related macular degeneration. *Nat. Genet.* 2011; **43**: 1232-1236.

459 49. Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S *et al.* Rare variants in CFI, C3 and  
460 C9 are associated with high risk of advanced age-related macular degeneration. *Nat. Genet.* 2013;  
461 **45**: 1366-1370.

462 50. van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, Mohlin FC *et al.* A functional variant in  
463 the CFI gene confers a high risk of age-related macular degeneration. *Nat. Genet.* 2013; **45**: 813-817.

464 51. Zhan X, Larson DE, Wang C, Koboldt DC, Sergeev YV, Fulton RS *et al.* Identification of a rare  
465 coding variant in complement 3 associated with age-related macular degeneration. *Nat. Genet.*  
466 2013; **45**: 1375-1379.

467 52. Helgason H, Sulem P, Duvvari MR, Luo H, Thorleifsson G, Stefansson H *et al.* A rare  
468 nonsynonymous sequence variant in C3 is associated with high risk of age-related macular  
469 degeneration. *Nat. Genet.* 2013; **45**: 1371-1374.

470 53. Duvvari MR, van de Ven JP, Geerlings MJ, Saksens NT, Bakker B, Henkes A *et al.* Whole Exome  
471 Sequencing in Patients with the Cuticular Drusen Subtype of Age-Related Macular Degeneration.  
472 *PLoS One* 2016; **11**: e0152047.

473 54. Geerlings MJ, Kremlitzka M, Bakker B, Nilsson SC, Saksens NT, Lechanteur YT *et al.* The Functional  
474 Effect of Rare Variants in Complement Genes on C3b Degradation in Patients With Age-Related  
475 Macular Degeneration. *JAMA Ophthalmol.* 2017; **135**: 39-46.

476 55. Hoffman JD, Cooke Bailey JN, D'Aoust L, Cade W, Ayala-Haedo J, Fuzzell D *et al.* Rare complement  
477 factor H variant associated with age-related macular degeneration in the Amish. *Invest. Ophthalmol.*  
478 *Vis. Sci.* 2014; **55**: 4455-4460.

479 56. Pras E, Kristal D, Shoshany N, Volodarsky D, Vulih I, Celniker G *et al.* Rare genetic variants in  
480 Tunisian Jewish patients suffering from age-related macular degeneration. *J. Med. Genet.* 2015; **52**:  
481 484-492.

482 57. Ratnapriya R, Zhan X, Fariss RN, Branham KE, Zipprer D, Chakarova CF *et al.* Rare and common  
483 variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration.  
484 *Hum. Mol. Genet.* 2014; **23**: 5827-5837.

485 58. Saksens NT, Geerlings MJ, Bakker B, Schick T, Daha MR, Fauser S *et al.* Rare Genetic Variants  
486 Associated With Development of Age-Related Macular Degeneration. *JAMA Ophthalmol.* 2016; **134**:  
487 287-293.

488 59. Yu Y, Triebwasser MP, Wong EK, Schramm EC, Thomas B, Reynolds R *et al.* Whole-exome  
489 sequencing identifies rare, functional CFH variants in families with macular degeneration. *Hum. Mol.*  
490 *Genet.* 2014; **23**: 5283-5293.

491 60. Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular  
492 degeneration: A review of rare genetic variants and implications for personalized treatment. *Mol.*  
493 *Immunol.* 2017; **84**: 65-76.

494 61. Triebwasser MP, Roberson ED, Yu Y, Schramm EC, Wagner EK, Raychaudhuri S *et al.* Rare  
495 Variants in the Functional Domains of Complement Factor H Are Associated With Age-Related  
496 Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2015; **56**: 6873-6878.

497 62. Wagner EK, Raychaudhuri S, Villalonga MB, Java A, Triebwasser MP, Daly MJ *et al.* Mapping rare,  
498 deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic  
499 levels in familial AMD. *Sci. Rep.* 2016; **6**: 31531.

500 63. Ferrara D, Seddon JM. Phenotypic Characterization of Complement Factor H R1210C Rare  
501 Genetic Variant in Age-Related Macular Degeneration. *JAMA Ophthalmol.* 2015; **133**: 785-791.

502 64. Kersten E, Geerlings MJ, den Hollander AI, de Jong EK, Fauser S, Peto T *et al.* Phenotype  
503 Characteristics of Patients With Age-Related Macular Degeneration Carrying a Rare Variant in the  
504 Complement Factor H Gene. *JAMA Ophthalmol.* 2017;.

505 65. Warwick A, Gibson J, Sood R, Lotery A. A rare penetrant TIMP3 mutation confers relatively late  
506 onset choroidal neovascularisation which can mimic age-related macular degeneration. *Eye (Lond)*  
507 2016; **30**: 488-491.

508 66. Cooke Bailey JN, Hoffman JD, Sardell RJ, Scott WK, Pericak-Vance MA, Haines JL. The Application  
509 of Genetic Risk Scores in Age-Related Macular Degeneration: A Review. *J. Clin. Med.* 2016; **5**:  
510 10.3390/jcm5030031.

511 67. Grassmann F, Fritsche LG, Keilhauer CN, Heid IM, Weber BH. Modelling the genetic risk in age-  
512 related macular degeneration. *PLoS One* 2012; **7**: e37979.

513 68. Hageman GS, Gehrs K, Lejnine S, Bansal AT, Deangelis MM, Guymer RH *et al.* Clinical validation of  
514 a genetic model to estimate the risk of developing choroidal neovascular age-related macular  
515 degeneration. *Hum. Genomics* 2011; **5**: 420-440.

516 69. Perlee LT, Bansal AT, Gehrs K, Heier JS, Csaky K, Allikmets R *et al.* Inclusion of genotype with  
517 fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic  
518 atrophy. *Ophthalmology* 2013; **120**: 1880-1892.

519 70. Seddon JM, Silver RE, Kwong M, Rosner B. Risk Prediction for Progression of Macular  
520 Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular  
521 Covariates. *Invest. Ophthalmol. Vis. Sci.* 2015; **56**: 2192-2202.

522 71. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-  
523 related macular degeneration using demographic, environmental, genetic, and ocular factors.  
524 *Ophthalmology* 2011; **118**: 2203-2211.

525 72. Chiu CJ, Mitchell P, Klein R, Klein BE, Chang ML, Gensler G *et al.* A risk score for the prediction of  
526 advanced age-related macular degeneration: development and validation in 2 prospective cohorts.  
527 *Ophthalmology* 2014; **121**: 1421-1427.

528 73. Schwartz SG, Hampton BM, Kovach JL, Brantley MA, Jr. Genetics and age-related macular  
529 degeneration: a practical review for the clinician. *Clin. Ophthalmol.* 2016; **10**: 1229-1235.

530 74. Ding Y, Liu Y, Yan Q, Fritsche LG, Cook RJ, Clemons T *et al.* Bivariate Analysis of Age-Related  
531 Macular Degeneration Progression Using Genetic Risk Scores. *Genetics* 2017; **206**: 119-133.

532 75. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association  
533 studies: markers with replicated highly significant odds ratios may be poor classifiers. *PLoS Genet.*  
534 2009; **5**: e1000337.

535 76. Kondo N, Bessho H, Honda S, Negi A. Complement factor H Y402H variant and risk of age-related  
536 macular degeneration in Asians: a systematic review and meta-analysis. *Ophthalmology* 2011; **118**:  
537 339-344.

538 77. Restrepo NA, Spencer KL, Goodloe R, Garrett TA, Heiss G, Buzkova P *et al.* Genetic determinants  
539 of age-related macular degeneration in diverse populations from the PAGE study. *Invest.*  
540 *Ophthalmol. Vis. Sci.* 2014; **55**: 6839-6850.

541 78. Spencer KL, Glenn K, Brown-Gentry K, Haines JL, Crawford DC. Population Differences in Genetic  
542 Risk for Age-related Macular Degeneration and Implications for Genetic Testing. *Arch. Ophthalmol.*  
543 2012; **130**: 116-117.

544 79. Stone EM, Aldave AJ, Drack AV, *et al.* Recommendations of the American Academy of  
545 Ophthalmology task force on genetic testing. Available from: [https://www.aaao.org/clinical-](https://www.aaao.org/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d)  
546 [statement/recommendations-genetic-testing-of-inherited-eye-d](https://www.aaao.org/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d). Accessed September 22, 2017.

547 80. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids  
548 for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized  
549 clinical trial. *JAMA* 2013; **309**: 2005-2015.

550 81. Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. CFH and ARMS2 genetic polymorphisms predict  
551 response to antioxidants and zinc in patients with age-related macular degeneration. *Ophthalmology*  
552 2013; **120**: 2317-2323.

553 82. Awh CC, Hawken S, Zanke BW. Treatment response to antioxidants and zinc based on CFH and  
554 ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. *Ophthalmology* 2015; **122**:  
555 162-169.

556 83. Chew EY, Klein ML, Clemons TE, Agron E, Abecasis GR. Genetic testing in persons with age-  
557 related macular degeneration and the use of the AREDS supplements: to test or not to test?  
558 *Ophthalmology* 2015; **122**: 212-215.

559 84. Chew EY, Klein ML, Clemons TE, Agron E, Ratnapriya R, Edwards AO *et al.* No clinically significant  
560 association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS  
561 report number 38. *Ophthalmology* 2014; **121**: 2173-2180.

562 85. Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, Schultz DW *et al.* CFH and  
563 LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular  
564 degeneration. *Ophthalmology* 2008; **115**: 1019-1025.

565 86. Seddon JM, Silver RE, Rosner B. Response to AREDS supplements according to genetic factors:  
566 survival analysis approach using the eye as the unit of analysis. *Br. J. Ophthalmol.* 2016; **100**: 1731-  
567 1737.

568 87. Csaky KG, Schachat AP, Kaiser PK, Small KW, Heier JS. The Use of Genetic Testing in the  
569 Management of Patients With Age-Related Macular Degeneration. *Journal of VitreoRetinal Diseases*  
570 2017; **1**: 75-78.

571 88. Stone EM. Genetic testing for age-related macular degeneration: not indicated now. *JAMA*  
572 *Ophthalmol.* 2015; **133**: 598-600.



573 89. Tsimbaris MK, Lopez-Galvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological  
574 and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in  
575 Patients with Neovascular AMD. *J. Ophthalmol.* 2016; **2016**: 4367631.

576 90. Riaz M, Lores-Motta L, Richardson AJ, Lu Y, Montgomery G, Omar A *et al.* GWAS study using DNA  
577 pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF  
578 treatment response in age-related macular degeneration. *Sci. Rep.* 2016; **6**: 37924.

579 91. Fauser S, Lambrou GN. Genetic predictive biomarkers of anti-VEGF treatment response in  
580 patients with neovascular age-related macular degeneration. *Surv. Ophthalmol.* 2015; **60**: 138-152.

581 92. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG *et al.* Pharmacogenetics  
582 for genes associated with age-related macular degeneration in the Comparison of AMD Treatments  
583 Trials (CATT). *Ophthalmology* 2013; **120**: 593-599.

584 93. Hagstrom SA, Ying GS, Pauer GJ, Huang J, Maguire MG, Martin DF *et al.* Endothelial PAS domain-  
585 containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the  
586 comparison of AMD treatments trials (CATT). *Ophthalmology* 2014; **121**: 1663-4.e1.

587 94. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG *et al.* VEGFA and  
588 VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy:  
589 comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol.* 2014;  
590 **132**: 521-527.

591 95. Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA *et al.* Pharmacogenetic  
592 associations with vascular endothelial growth factor inhibition in participants with neovascular age-  
593 related macular degeneration in the IVAN Study. *Ophthalmology* 2013; **120**: 2637-2643.

594 96. Hagstrom SA, Ying GS, Maguire MG, Martin DF, CATT Research Group, Gibson J *et al.* VEGFR2  
595 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-  
596 Related Macular Degeneration. *Ophthalmology* 2015; **122**: 1563-1568.

597 97. Hong N, Shen Y, Yu CY, Wang SQ, Tong JP. Association of the polymorphism Y402H in the CFH  
598 gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic  
599 review and meta-analysis. *Acta Ophthalmol.* 2016; **94**: 334-345.

600 98. Hu Z, Xie P, Ding Y, Yuan D, Liu Q. Association between variants A69S in ARMS2 gene and  
601 response to treatment of exudative AMD: a meta-analysis. *Br. J. Ophthalmol.* 2015; **99**: 593-598.

602 99. Wu M, Xiong H, Xu Y, Xiong X, Zou H, Zheng M *et al.* Association between VEGF-A and VEGFR-2  
603 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-  
604 analysis. *Br. J. Ophthalmol.* 2017; **101**: 976-984.

605 100. Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y. Pharmacogenetics of Complement Factor H  
606 Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.  
607 *Sci. Rep.* 2015; **5**: 14517.

608 101. Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A *et al.* Targeting factor D of the  
609 alternative complement pathway reduces geographic atrophy progression secondary to age-related  
610 macular degeneration. *Sci. Transl. Med.* 2017; **9**: 10.1126/scitranslmed.aaf1443.

611 102. Roche. Roche provides update on first lapaizumab phase III study for geographic atrophy, an  
612 advanced form of age-related macular degeneration. Available from:  
613 <https://www.roche.com/media/store/releases/med-cor-2017-09-08b.htm>. Accessed September 22,  
614 2017.  
615

103. Apellis. Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration. Available from: <http://apellis.com/pdfs/Press%20Release%20FILLY%2012%20Month%20Results%20FINAL%20FINAL%20170823.pdf>. Accessed September 22, 2017.

## TITLES AND LEGENDS TO FIGURES

**Figure 1.** An example receiver operating characteristic (ROC) curve. The solid black line represents an area under the ROC (AUC) of 0.5, random chance. The dashed black line indicates an AUC of 1.0, a perfect model. The dotted grey line represents a ROC curve with an AUC between 0.5 and 1.0, as may be generated by a predictive risk model. Specificity decreases with increasing sensitivity.

